Dongyang Guangyao (06887) rose more than 4% in early trading. As of the time of writing, it was up 4.06%, trading at HKD 46.68, with a turnover of HKD 13.8169 million.
According to Zhitong Finance, Dongyang Guangyao (06887) rose more than 4% in early trading. As of the time of writing, it was up 4.06%, trading at HKD 46.68, with a turnover of HKD 13.8169 million.
In terms of news, on January 26, Dongyang Guangyao and XtalPi Holdings announced the signing of a significant strategic cooperation agreement. This collaboration marks a strategic leap for Dongyang Guangyao as it fully embraces the 'AI + robotics' R&D paradigm to achieve an upgrade in its research capabilities. It also serves as another strong validation of the commercial value of XtalPi Holdings’ general-purpose AI platform within the context of large pharmaceutical enterprises.
It was revealed that the two parties plan to establish a joint venture, deeply integrating the technological advantages of XtalPi Holdings’ AI + robotics drug discovery platform with Dongyang Guangyao’s extensive experience in multi-target R&D data, biological insights, and pipeline development. By jointly building an AI + robotics laboratory and developing non-clinical drug large models, they aim to address numerous long-standing challenges in drug discovery, achieving comprehensive cooperation in foundational technologies, new drug pipeline development, and commercialization. In this collaboration, Dongyang Guangyao is expected to invest hundreds of millions of yuan. The two companies aim to create a leading AI-driven drug discovery engine in the industry and achieve technology export, establishing a diversified profit model based on 'pipeline co-creation + technology win-win.'
